New Leadership, Innovative Technology Take Neurosciences at Capital Health to the Next Level

Capital Institute for Neurosciences has the reputation in central New Jersey and the greater Delaware Valley for providing advanced care to patients with complex, neurological conditions affecting the brain and spine. As part of its commitment to advancing brain and spine care throughout the region, Capital Health has welcomed new leadership to the Institute.

Dr. Michael Stiefel, a fellowship trained, board certified neurosurgeon specializing in cerebrovascular and endovascular neurosurgery, has joined Capital Health as the director of its Capital Institute for Neurosciences and director of the Stroke & Cerebrovascular Center. Dr. Stiefel oversees all neurosurgical and neurological services offered at the Institute as well as Capital Health’s Comprehensive Stroke Program, Neurosurgical Intensive Care Unit, and neuroscience research activities.

“Dr. Stiefel’s experience clearly demonstrates his commitment to excellence and his leadership will result in even greater advances for our patients,” said Al Maghazehe, president and CEO of Capital Health. “I have no doubt that our Capital Institute for Neurosciences will further elevate the level of care patients can expect to receive at an advanced neuroscience center like the one we opened eight years ago.”

Dr. Stiefel completed fellowships at both the University of Pennsylvania and Barrow Neurological Institute, and is trained in both open neurosurgical approaches and endovascular techniques.

Prior to joining Capital Health, Dr. Stiefel practiced at Westchester Medical Center in New York, where he established one of the largest comprehensive neurovascular programs for the treatment of stroke, aneurysms, and brain hemorrhages in the New York/Connecticut region and Hudson Valley.

“One of the most impressive things about Capital Health, and a big part of why I decided to join the Institute, is its willingness to invest in and promote highly specialized, advanced care for patients with brain and spine diseases,” said Dr. Stiefel.

“For patients in the region, that means access to extensive experience in caring for neurologic issues, whether they are time sensitive emergencies like stroke, or conditions that require ongoing specialized care such as Parkinson’s Disease, brain tumors, headache, spine disorders or complex and difficult to treat pain. I look forward to working with the impressive group of physicians and other providers who are already part of the Capital Health team to continually advance the care we can provide to our patients.”

As a nationally recognized leader in stroke research, Dr. Stiefel has been at the forefront of trialing new devices for the treatment of ischemic stroke and cerebral aneurysms. He was first in the New York region to use the Solitaire Stent-Triever for stroke (after FDA approval) and is currently one of the most experienced users of the Pipeline Embolization Device for the treatment of aneurysms.

Visit capitalneuro.org to learn more about Dr. Stiefel and the Capital Institute for Neurosciences.

Facebook Comments